Insider Transactions in Q4 2025 at Bicara Therapeutics Inc. (BCAX)
Insider Transaction List (Q4 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 16
2025
|
Claire Mazumdar Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
24,103
-7.22%
|
$433,854
$18.83 P/Share
|
|
Oct 16
2025
|
Claire Mazumdar Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
24,103
+6.73%
|
$72,309
$3.79 P/Share
|
|
Oct 15
2025
|
Ryan Cohlhepp President and COO |
SELL
Open market or private sale
|
Direct |
12,500
-3.01%
|
$225,000
$18.16 P/Share
|
|
Oct 15
2025
|
Ryan Cohlhepp President and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+3.66%
|
$24,000
$3.79 P/Share
|
|
Oct 15
2025
|
Claire Mazumdar Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
13,289
-4.11%
|
$239,202
$18.84 P/Share
|
|
Oct 15
2025
|
Claire Mazumdar Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,289
+3.95%
|
$39,867
$3.79 P/Share
|
|
Oct 13
2025
|
Claire Mazumdar Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
11,445
-3.56%
|
$206,010
$18.92 P/Share
|
|
Oct 13
2025
|
Claire Mazumdar Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,445
+3.44%
|
$34,335
$3.79 P/Share
|
|
Oct 09
2025
|
Ivan Hyep Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
6,415
-4.23%
|
$115,470
$18.23 P/Share
|
|
Oct 09
2025
|
Ivan Hyep Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,415
+4.06%
|
$19,245
$3.79 P/Share
|
|
Oct 09
2025
|
David Raben Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
22,000
-38.26%
|
$396,000
$18.45 P/Share
|
|
Oct 09
2025
|
David Raben Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
22,000
+27.67%
|
$66,000
$3.79 P/Share
|
|
Oct 08
2025
|
Ivan Hyep Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,627
-3.73%
|
$101,286
$18.21 P/Share
|
|
Oct 08
2025
|
Ivan Hyep Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,627
+3.59%
|
$16,881
$3.79 P/Share
|
|
Oct 07
2025
|
Ryan Cohlhepp President and COO |
SELL
Open market or private sale
|
Direct |
10,900
-2.58%
|
$196,200
$18.06 P/Share
|
|
Oct 07
2025
|
Ryan Cohlhepp President and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+3.61%
|
$24,000
$3.79 P/Share
|
|
Oct 07
2025
|
Ivan Hyep Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
18,244
-11.15%
|
$328,392
$18.22 P/Share
|
|
Oct 07
2025
|
Ivan Hyep Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,244
+10.03%
|
$54,732
$3.79 P/Share
|
|
Oct 06
2025
|
Ryan Cohlhepp President and COO |
SELL
Open market or private sale
|
Direct |
39,600
-8.42%
|
$712,800
$18.06 P/Share
|
|
Oct 06
2025
|
Ryan Cohlhepp President and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
24,000
+8.92%
|
$72,000
$3.79 P/Share
|
|
Oct 06
2025
|
Ivan Hyep Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
6,514
-4.29%
|
$117,252
$18.17 P/Share
|
|
Oct 06
2025
|
Ivan Hyep Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,514
+4.11%
|
$19,542
$3.79 P/Share
|